Coherus BioSciences Inc (NAS:CHRS)
$ 1.78 0.02 (1.14%) Market Cap: 204.21 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Bank of America Global Healthcare Conference Transcript

May 11, 2023 / 05:15PM GMT
Release Date Price: $5.19 (-12.18%)
Bhavin Patel
BofA Securities, Research Division - Team Developer

Yes. My name is Bhavin Patel, one of the biopharma analysts here at BofA. I'm here with Denny, CEO of Coherus.

Questions & Answers

Bhavin Patel
BofA Securities, Research Division - Team Developer

So to jump right into the Q&A. You reported 1Q, and the stock is down to about $5 a share trading at 52-week lows. And I wanted to get your thoughts on what do you think is the reason? And is it an overreaction to the maybe miss on UDENYCA?

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Well, sure. I think it's a little overdone. Frankly, I've had better weeks than this week. But I think you have to put it in perspective in the long-term view of the company. Q1 was the last quarter in which we had only one undifferentiated presentation for UDENYCA. So this is a market in which we've said many times there was additional competitors and entrants. And that put significant pressure on competitive pricing dynamics and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot